Titre : Vincristine

Vincristine : Questions médicales fréquentes

Nom anglais: Vincristine

Descriptor UI: D014750

Tree Number: D03.633.100.496.500.500.681.827.817

Termes MeSH sélectionnés :

Hyperuricemia

Questions fréquentes et termes MeSH associés

Diagnostic 2

#1

Comment la vincristine est-elle utilisée dans le diagnostic ?

La vincristine n'est pas un outil de diagnostic, mais un traitement pour des cancers diagnostiqués.
Vincristine Cancer Diagnostic
#2

Quels tests précèdent l'administration de vincristine ?

Des tests sanguins et des examens d'imagerie sont effectués pour évaluer la maladie.
Tests de laboratoire Imagerie médicale Vincristine

Symptômes 2

#1

Quels sont les effets secondaires de la vincristine ?

Les effets secondaires incluent neuropathie, constipation, et fatigue.
Effets secondaires Neuropathie Vincristine
#2

La vincristine cause-t-elle des douleurs ?

Oui, elle peut provoquer des douleurs neuropathiques chez certains patients.
Douleur Neuropathie Vincristine

Prévention 2

#1

Peut-on prévenir les effets secondaires de la vincristine ?

Des mesures préventives incluent une surveillance étroite et des médicaments pour les symptômes.
Prévention Effets secondaires Vincristine
#2

Y a-t-il des recommandations avant le traitement par vincristine ?

Oui, une évaluation médicale complète est recommandée avant le traitement.
Évaluation médicale Vincristine Préparation au traitement

Traitements 2

#1

Avec quels médicaments la vincristine est-elle souvent combinée ?

Elle est souvent combinée avec la prednisone et d'autres agents chimiothérapeutiques.
Chimiothérapie Vincristine Prednisone
#2

Comment la vincristine est-elle administrée ?

La vincristine est administrée par voie intraveineuse, généralement en cycle.
Administration intraveineuse Vincristine Chimiothérapie

Complications 2

#1

Quelles complications peuvent survenir avec la vincristine ?

Des complications incluent des infections, des troubles neurologiques et des problèmes gastro-intestinaux.
Complications Infections Vincristine
#2

La vincristine peut-elle causer des problèmes cardiaques ?

Bien que rare, des problèmes cardiaques peuvent survenir, nécessitant une surveillance.
Problèmes cardiaques Vincristine Surveillance médicale

Facteurs de risque 2

#1

Qui est à risque d'effets indésirables de la vincristine ?

Les patients âgés et ceux avec des antécédents de neuropathie sont à risque accru.
Facteurs de risque Neuropathie Vincristine
#2

Les antécédents médicaux influencent-ils le traitement par vincristine ?

Oui, des antécédents de maladies neurologiques peuvent affecter le traitement.
Antécédents médicaux Vincristine Neurologie
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Vincristine : Questions médicales les plus fréquentes", "headline": "Vincristine : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Vincristine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-05-27", "dateModified": "2025-02-21", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Vincristine" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Alcaloïdes de Vinca", "url": "https://questionsmedicales.fr/mesh/D014748", "about": { "@type": "MedicalCondition", "name": "Alcaloïdes de Vinca", "code": { "@type": "MedicalCode", "code": "D014748", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.633.100.496.500.500.681.827" } } }, "about": { "@type": "MedicalCondition", "name": "Vincristine", "alternateName": "Vincristine", "code": { "@type": "MedicalCode", "code": "D014750", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Wenjian Yang", "url": "https://questionsmedicales.fr/author/Wenjian%20Yang", "affiliation": { "@type": "Organization", "name": "Hematological Malignancies Program and Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA." } }, { "@type": "Person", "name": "Deqing Pei", "url": "https://questionsmedicales.fr/author/Deqing%20Pei", "affiliation": { "@type": "Organization", "name": "Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA." } }, { "@type": "Person", "name": "Cheng Cheng", "url": "https://questionsmedicales.fr/author/Cheng%20Cheng", "affiliation": { "@type": "Organization", "name": "Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA." } }, { "@type": "Person", "name": "William E Evans", "url": "https://questionsmedicales.fr/author/William%20E%20Evans", "affiliation": { "@type": "Organization", "name": "Hematological Malignancies Program and Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA." } }, { "@type": "Person", "name": "Richard H Ho", "url": "https://questionsmedicales.fr/author/Richard%20H%20Ho", "affiliation": { "@type": "Organization", "name": "Vanderbilt University Medical Center, Nashville, TN." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Advances in pharmacotherapies for hyperuricemia.", "datePublished": "2023-03-30", "url": "https://questionsmedicales.fr/article/36999206", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1080/14656566.2023.2197591" } }, { "@type": "ScholarlyArticle", "name": "Prevalence of High-Altitude Polycythemia and Hyperuricemia and Risk Factors for Hyperuricemia in High-Altitude Immigrants.", "datePublished": "2023-04-04", "url": "https://questionsmedicales.fr/article/37015076", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1089/ham.2022.0133" } }, { "@type": "ScholarlyArticle", "name": "Exercise and hyperuricemia: an opinion article.", "datePublished": "2024-08-26", "url": "https://questionsmedicales.fr/article/39183708", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1080/07853890.2024.2396075" } }, { "@type": "ScholarlyArticle", "name": "Susceptibility genes of hyperuricemia and gout.", "datePublished": "2022-08-04", "url": "https://questionsmedicales.fr/article/35922835", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s41065-022-00243-y" } }, { "@type": "ScholarlyArticle", "name": "Hyperuricemia is accompanied by elevated peripheral CD4", "datePublished": "2023-08-02", "url": "https://questionsmedicales.fr/article/37532790", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-023-39775-2" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Composés hétérocycliques", "item": "https://questionsmedicales.fr/mesh/D006571" }, { "@type": "ListItem", "position": 3, "name": "Composés hétérocycliques à cycles fusionnés", "item": "https://questionsmedicales.fr/mesh/D000072471" }, { "@type": "ListItem", "position": 4, "name": "Composés hétérobicycliques", "item": "https://questionsmedicales.fr/mesh/D006574" }, { "@type": "ListItem", "position": 5, "name": "Indolizine", "item": "https://questionsmedicales.fr/mesh/D007212" }, { "@type": "ListItem", "position": 6, "name": "Indolizidines", "item": "https://questionsmedicales.fr/mesh/D054836" }, { "@type": "ListItem", "position": 7, "name": "Alcaloïdes indoliques", "item": "https://questionsmedicales.fr/mesh/D026121" }, { "@type": "ListItem", "position": 8, "name": "Alcaloïdes formés par condensation de sécologanine et de tryptamine", "item": "https://questionsmedicales.fr/mesh/D046948" }, { "@type": "ListItem", "position": 9, "name": "Alcaloïdes de Vinca", "item": "https://questionsmedicales.fr/mesh/D014748" }, { "@type": "ListItem", "position": 10, "name": "Vincristine", "item": "https://questionsmedicales.fr/mesh/D014750" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Vincristine - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Vincristine", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-08", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Vincristine", "description": "Comment la vincristine est-elle utilisée dans le diagnostic ?\nQuels tests précèdent l'administration de vincristine ?", "url": "https://questionsmedicales.fr/mesh/D014750?mesh_terms=Hyperuricemia#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Vincristine", "description": "Quels sont les effets secondaires de la vincristine ?\nLa vincristine cause-t-elle des douleurs ?", "url": "https://questionsmedicales.fr/mesh/D014750?mesh_terms=Hyperuricemia#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Vincristine", "description": "Peut-on prévenir les effets secondaires de la vincristine ?\nY a-t-il des recommandations avant le traitement par vincristine ?", "url": "https://questionsmedicales.fr/mesh/D014750?mesh_terms=Hyperuricemia#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Vincristine", "description": "Avec quels médicaments la vincristine est-elle souvent combinée ?\nComment la vincristine est-elle administrée ?", "url": "https://questionsmedicales.fr/mesh/D014750?mesh_terms=Hyperuricemia#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Vincristine", "description": "Quelles complications peuvent survenir avec la vincristine ?\nLa vincristine peut-elle causer des problèmes cardiaques ?", "url": "https://questionsmedicales.fr/mesh/D014750?mesh_terms=Hyperuricemia#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Vincristine", "description": "Qui est à risque d'effets indésirables de la vincristine ?\nLes antécédents médicaux influencent-ils le traitement par vincristine ?", "url": "https://questionsmedicales.fr/mesh/D014750?mesh_terms=Hyperuricemia#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment la vincristine est-elle utilisée dans le diagnostic ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "La vincristine n'est pas un outil de diagnostic, mais un traitement pour des cancers diagnostiqués." } }, { "@type": "Question", "name": "Quels tests précèdent l'administration de vincristine ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins et des examens d'imagerie sont effectués pour évaluer la maladie." } }, { "@type": "Question", "name": "Quels sont les effets secondaires de la vincristine ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires incluent neuropathie, constipation, et fatigue." } }, { "@type": "Question", "name": "La vincristine cause-t-elle des douleurs ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut provoquer des douleurs neuropathiques chez certains patients." } }, { "@type": "Question", "name": "Peut-on prévenir les effets secondaires de la vincristine ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Des mesures préventives incluent une surveillance étroite et des médicaments pour les symptômes." } }, { "@type": "Question", "name": "Y a-t-il des recommandations avant le traitement par vincristine ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une évaluation médicale complète est recommandée avant le traitement." } }, { "@type": "Question", "name": "Avec quels médicaments la vincristine est-elle souvent combinée ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Elle est souvent combinée avec la prednisone et d'autres agents chimiothérapeutiques." } }, { "@type": "Question", "name": "Comment la vincristine est-elle administrée ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "La vincristine est administrée par voie intraveineuse, généralement en cycle." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec la vincristine ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent des infections, des troubles neurologiques et des problèmes gastro-intestinaux." } }, { "@type": "Question", "name": "La vincristine peut-elle causer des problèmes cardiaques ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Bien que rare, des problèmes cardiaques peuvent survenir, nécessitant une surveillance." } }, { "@type": "Question", "name": "Qui est à risque d'effets indésirables de la vincristine ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Les patients âgés et ceux avec des antécédents de neuropathie sont à risque accru." } }, { "@type": "Question", "name": "Les antécédents médicaux influencent-ils le traitement par vincristine ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents de maladies neurologiques peuvent affecter le traitement." } } ] } ] }
Dr Olivier Menir

Contenu validé par Dr Olivier Menir

Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale

Validation scientifique effectuée le 21/02/2025

Contenu vérifié selon les dernières recommandations médicales

En savoir plus sur Dr Menir

Auteurs principaux

Wenjian Yang

3 publications dans cette catégorie

Affiliations :
  • Hematological Malignancies Program and Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Publications dans "Vincristine" :

Deqing Pei

3 publications dans cette catégorie

Affiliations :
  • Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Publications dans "Vincristine" :

Cheng Cheng

3 publications dans cette catégorie

Affiliations :
  • Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Publications dans "Vincristine" :

William E Evans

3 publications dans cette catégorie

Affiliations :
  • Hematological Malignancies Program and Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Publications dans "Vincristine" :

Richard H Ho

3 publications dans cette catégorie

Affiliations :
  • Vanderbilt University Medical Center, Nashville, TN.
Publications dans "Vincristine" :

Sima Jeha

2 publications dans cette catégorie

Affiliations :
  • Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Publications dans "Vincristine" :

Ching-Hon Pui

2 publications dans cette catégorie

Affiliations :
  • Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Publications dans "Vincristine" :

Mirjam E van de Velde

2 publications dans cette catégorie

Affiliations :
  • Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, 1081 HV Amsterdam, The Netherlands.
  • Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Publications dans "Vincristine" :

Aniek Uittenboogaard

2 publications dans cette catégorie

Affiliations :
  • Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, 1081 HV Amsterdam, The Netherlands.
  • Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.
Publications dans "Vincristine" :

Gertjan J L Kaspers

2 publications dans cette catégorie

Affiliations :
  • Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, 1081 HV Amsterdam, The Netherlands.
  • Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.
Publications dans "Vincristine" :

Esperanza Herradón

2 publications dans cette catégorie

Affiliations :
  • Departamento de Ciencias Básicas de la Salud, Facultad de Ciencias de la Salud, Universidad Rey Juan Carlos, Alcorcón, Spain.
  • Unidad Asociada al Instituto de Química Medica (IQM) del Consejo Superior de Investigaciones Científicas (CSIC), Universidad Rey Juan Carlos, Alcorcón, Spain.
  • High Performance Research Group in Experimental Pharmacology (Pharmakom-URJC), URJC, Alcorcón, Spain.
Publications dans "Vincristine" :

Visitación López-Miranda

2 publications dans cette catégorie

Affiliations :
  • Departamento de Ciencias Básicas de la Salud, Facultad de Ciencias de la Salud, Universidad Rey Juan Carlos, Alcorcón, Spain.
  • Unidad Asociada al Instituto de Química Medica (IQM) del Consejo Superior de Investigaciones Científicas (CSIC), Universidad Rey Juan Carlos, Alcorcón, Spain.
  • High Performance Research Group in Experimental Pharmacology (Pharmakom-URJC), URJC, Alcorcón, Spain.
Publications dans "Vincristine" :

Yang Li

2 publications dans cette catégorie

Affiliations :
  • Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, PR China.
Publications dans "Vincristine" :

Jing Huang

2 publications dans cette catégorie

Affiliations :
  • Department of Psychiatry, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China; Mental Health Institute of the Second Xiangya Hospital, Central South University, Chinese National Clinical Research Center on Mental Disorders (xiangya), Chinese National Technology Institute on Mental Disorders, Hunan Key Laboratory of Psychiatry and Mental Health, Changsha, Hunan 410011, China.
Publications dans "Vincristine" :

Johnny Donovan

2 publications dans cette catégorie

Affiliations :
  • Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
Publications dans "Vincristine" :

Zicheng Deng

2 publications dans cette catégorie

Affiliations :
  • Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
  • The Materials Science and Engineering Program, College of Engineering and Applied Science, University of Cincinnati, Cincinnati, OH, United States.
  • Center for Lung Regenerative Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
Publications dans "Vincristine" :

Fenghua Bian

2 publications dans cette catégorie

Affiliations :
  • Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
Publications dans "Vincristine" :

Samriddhi Shukla

2 publications dans cette catégorie

Affiliations :
  • Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
Publications dans "Vincristine" :

Jose Gomez-Arroyo

2 publications dans cette catégorie

Affiliations :
  • Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, United States.
  • Division of Pulmonary and Critical Care and Sleep Medicine, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH, United States.
Publications dans "Vincristine" :

Donglu Shi

2 publications dans cette catégorie

Affiliations :
  • The Materials Science and Engineering Program, College of Engineering and Applied Science, University of Cincinnati, Cincinnati, OH, United States.
Publications dans "Vincristine" :

Sources (776 au total)

Advances in pharmacotherapies for hyperuricemia.

Apr 2023
DOI: 10.1080/14656566.2023.2197591 PMID: 36999206

Hyperuricemia is an overlooked cardiovascular and renal risk factor. Epidemiological and genetic studies have shown an independent role of uric acid in the risk of coronary artery disease, heart failu... In the present review, we summarized current therapeutic indications and options for the treatment of symptomatic and asymptomatic hyperuricemia. Furthermore, we searched the recent literature (last 5... Future large well-designed clinical trials on the role of hypouricemic agents in nephroprotection and cardiovascular prevention and treatment are warranted and may extend their indications and use, wi...

Humans Hyperuricemia Uric Acid Kidney Enzyme Inhibitors +2 autres

Pyrazinamide-induced Hyperuricemia in Pulmonary Tuberculosis Patients.

01 Jul 2024
DOI: 10.4103/ijmy.ijmy_178_23 PMID: 39277890

Pyrazinamide is one of the antitubercular drugs used for 2 months in the intensive phase. One of the adverse effects of pyrazinamide is hyperuricemia, with a symptom of arthralgia. This study aims to ... It was an analytic observational study with a prospective cohort design. Three ml of blood from each pulmonary TB patient was withdrawn to examine uric acid levels before and after 2 months of treatme... Twenty pulmonary TB patients met the inclusion criteria in this study. Eight out of 12 (60%) TB patients showed uric acid levels ≥7 mg/dl and 8 of them (66.6%) showed symptoms of arthralgia. The media... Uric acid levels significantly increased during the intensive phase. Pulmonary TB patients with hyperuricemia are a risk factor for arthralgia....

Humans Hyperuricemia Pyrazinamide Male Tuberculosis, Pulmonary +10 autres

Hyperuricemia is associated with the progression of IgA nephropathy in children.

09 2023
DOI: 10.1038/s41390-023-02538-w PMID: 36914808

The objective of the study was to explore the potential biomarkers and risk factors in children with immunoglobulin A nephropathy (IgAN).... Untargeted metabolomics analysis was performed on children with IgAN before and after treatment. Subsequently, a retrospective study involving the past 15 years and a follow-up study were performed to... Serum metabolomics analyses showed that levels of serum xanthosine were closely related to the outcome of IgAN, and KEGG analyses showed that differential metabolites were significantly enriched in pu... We first performed a dynamic metabolomics study to reveal that hyperuricemia is closely related to the progression of IgAN in children. Then retrospective and follow-up studies confirmed that hyperuri... We first performed a dynamic metabolomics study to reveal that hyperuricemia was closely related to the progression of IgAN in children. Retrospective analyses in past 15 years confirmed that IgAN chi...

Female Humans Child Glomerulonephritis, IGA Retrospective Studies +4 autres

Association of hyperuricemia combined with sarcopenia on ASCVD risk.

27 06 2023
DOI: 10.1186/s12872-023-03336-2 PMID: 37370012

Hyperuricemia and sarcopenia are both strongly linked to an increased risk of atherosclerotic cardiovascular disease (ASCVD), and this study was designed to look into the interactive effects of hyperu... This study collected information from patients (N = 2647) who underwent health check-ups at the Health Care Building of Wuhan Union Hospital between January 2019 and December 2020. Skeletal muscle mas... The prevalence of hyperuricemia and sarcopenia was 23.57% and 15.34%, respectively. The occurrence of cardiovascular risk factors such as obesity, hypertension, diabetes mellitus, chronic kidney disea... Hyperuricemia is independently associated with high-risk ASCVD; Sarcopenia and high-risk ASCVD did not show an independent relationship, but there was a synergistic effect of the two on ASCVD risk, wh...

Humans Sarcopenia Hyperuricemia Atherosclerosis Diabetes Mellitus +3 autres

The biomarkers discovery of hyperuricemia and gout: proteomics and metabolomics.

2023
DOI: 10.7717/peerj.14554 PMID: 36632144

Hyperuricemia and gout are a group of disorders of purine metabolism. In recent years, the incidence of hyperuricemia and gout has been increasing, which is a severe threat to people's health. Several... We used professional databases including PubMed, Web of Science to conduct the literature review. This review addresses the current landscape of hyperuricemia and gout biomarkers with a focus on prote... Proteomic methods are used to identify differentially expressed proteins to find specific biomarkers. These findings may be suggestive for the diagnosis and treatment of hyperuricemia and gout to expl... We suggest some possible relationships of potential biomarkers with inflammatory episodes, complement activation, and metabolic pathways. These biomarkers are able to distinguish between different sta...

Humans Hyperuricemia Proteomics Gout Uric Acid +1 autres